Irradiation affects cellular properties and Eph receptor expression in human melanoma cells

Cell Adhesion and Migration

Volumn 6, Issue 2, 2012, Pages 113-125

  Mosch, Birgit ^a   Pietzsch, Doreen ^a   Pietzsch, Jens ^a  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Eph receptors; Ephrins; Malignant skin cancer; Metastasis; Radiation therapy

Indexed keywords

EPHRIN A2; EPHRIN A3; EPHRIN RECEPTOR; FOCAL ADHESION KINASE; LIGAND; PROTEIN TYROSINE KINASE;

ARTICLE; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MELANOMA CELL; METASTASIS INHIBITION; METASTASIS POTENTIAL; PILOT STUDY; PROTEIN EXPRESSION; RADIATION RESPONSE; UPREGULATION; X IRRADIATION;

EID: 84863976469     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.20655     Document Type: Article

References (67)

1. Kargiotis O, Geka A, Rao JS, Kyritsis AP. Effects of irradiation on tumor cell survival, invasion and angiogenesis. J Neurooncol 2010; 100:323-38; PMID: 20449629; http://dx.doi.org/10.1007/s11060-010-0199-4
2. Akino Y, Teshima T, Kihara A, Kodera-Suzumoto Y, Inaoka M, Higashiyama S, et al. Carbon-ion beam irradiation effectively suppresses migration and invasion of human non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 2009; 75:475-81; PMID:19735871; http://dx.doi.org/10.1016/j.ijrobp.2008.12.090
3. Cordes N, Hansmeier B, Beinke C, Meineke V, van Beuningen D. Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer 2003; 89:2122-32; PMID:14647148; http://dx.doi.org/10.1038/sj.bjc.6601429
4. Goetze K, Scholz M, Taucher-Scholz G, Mueller-Klieser W. Tumor cell migration is not influenced by p21 in colon carcinoma cell lines after irradiation with X-ray or (12)C heavy ions. Radiat Environ Biophys 2010; 49:427-35; PMID:20535615; http://dx.doi.org/10.1007/s00411-010-0297-x
5. Ristic-Fira AM, Todorovic DV, Koricanac LB, Petrovic IM, Valastro LM, Cirrone PG, et al. Response of a human melanoma cell line to low and high ionizing radiation. Ann N Y Acad Sci 2007; 1095:165-74; PMID: 17404029; http://dx.doi.org/10.1196/annals.1397.020
6. Mosch B, Mueller K, Steinbach J, Pietzsch J. Influence of irradiation on metabolism and metastatic potential of B16-F10 melanoma cells. Int J Radiat Biol 2009; 85:1002-12; PMID:19895277; http://dx.doi.org/10.3109/09553000903258871
7. Baluna RG, Eng TY, Thomas CR. Adhesion molecules in radiotherapy. Radiat Res 2006; 166:819-31; PMID: 17149971; http://dx.doi.org/10.1667/RR0380.1
8. Jung JW, Hwang SY, Hwang JS, Oh ES, Park S, Han IO. Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur J Cancer 2007; 43:1214-24; PMID:17379505; http://dx.doi.org/10.1016/j.ejca.2007.01.034
9. Ogata T, Teshima T, Kagawa K, Hishikawa Y, Takahashi Y, Kawaguchi A, et al. Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res 2005; 65:113-20; PMID:15665286
10. Onoda JM, Kantak SS, Piechocki MP, Awad W, Chea R, Liu B, et al. Inhibition of radiation-enhanced expression of integrin and metastatic potential in B16 melanoma cells by a lipoxygenase inhibitor. Radiat Res 1994; 140:410-8; PMID:7972695; http://dx.doi.org/10.2307/3579120
11. Tsutsumi K, Tsuda M, Yazawa N, Nakamura H, Ishihara S, Haga H, et al. Increased motility and invasiveness in tumor cells that survive 10 Gy irradiation. Cell Struct Funct 2009; 34:89-96; PMID: 19724156; http://dx.doi.org/10.1247/csf.09006
12. Fujita M, Otsuka Y, Yamada S, Iwakawa M, Imai T. X-ray irradiation and Rho-kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa-2, which exhibits mesenchymal and amoeboid motility. Cancer Sci 2011; 102:792-8; PMID:21214671; http://dx.doi.org/10.1111/ j.1349-7006.2011.01852.x
13. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radio-therapy of human glioblastoma. Cancer Res 2001; 61:2744-50; PMID:11289157
14. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001; 61:2207-11; PMID:11280788
15. Rofstad EK, Mathiesen B, Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res 2004; 64:13-8; PMID:14729600; http://dx.doi.org/10.1158/0008-5472.CAN-03-2658
16. Akimoto T, Mitsuhashi N, Saito Y, Ebara T, Niibe H. Effect of radiation on the expression of E-cadherin and alpha-catenin and invasive capacity in human lung cancer cell line in vitro. Int J Radiat Oncol Biol Phys 1998; 41:1171-6; PMID:9719129; http://dx.doi.org/10.1016/S0360-3016(98)00176-X
17. Chatterjee A, Rojas A, Hodgkiss RJ. Induction of lethal mutations in experimental tumours after single and fractionated irradiations in vivo. Int J Radiat Biol 1998; 74:119-27; PMID:9687981; http://dx.doi.org/10.1080/ 095530098141780
18. Liu ZZ, Huang WY, Lin JS, Li XS, Liang KH, Huang JL. Cell cycle and radiosensitivity of progeny of irradiated primary cultured human hepatocarcinoma cells. World J Gastroenterol 2005; 11:7033-5; PMID: 16437612
19. Wimmer-Kleikamp SH, Lackmann M. Eph-modulated cell morphology, adhesion and motility in carcinogenesis. IUBMB Life 2005; 57:421-31; PMID:16012051; http://dx.doi.org/10.1080/15216540500138337
20. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002; 13:75-85; PMID:11750881; http://dx.doi.org/10.1016/S1359-6101(01)00031-4
21. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002; 3:475-86; PMID:12094214; http://dx.doi.org/10.1038/nrm856
22. Castaño J, Davalos V, Schwartz S, Jr., Arango D. EPH receptors in cancer. Histol Histopathol 2008; 23:1011-23; PMID:18498077
23. Mosch B, Reissenweber B, Neuber C, Pietzsch J. Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol 2010; 2010:135285; PMID:20224755; http://dx.doi.org/10.1155/2010/135285
24. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10:165-80; PMID:20179713; http://dx.doi.org/10.1038/nrc2806
25. Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 2003; 20:59-68; PMID:12650608; http://dx.doi.org/10.1023/A:1022546620495
26. Easty DJ, Hill SP, HsuMY, FallowfieldME, Florenes VA, Herlyn M, et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999; 84:494-501; PMID:10502726; http://dx.doi.org/10.1002/(SICI)1097-0215(19991022) 84:5,494::AID-IJC8.3.0.CO;2-O
27. Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS, Hendrix MJ, et al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 2009; 8:279-88; PMID:19223760; http://dx.doi.org/10.4161/cbt.8.3.7485
28. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 2005; 24:7859-68; PMID:16103880; http://dx.doi.org/10.1038/ sj.onc.1208937
29. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61:2301-6; PMID:11280802
30. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999; 41:275-80; PMID:10544301; http://dx.doi.org/10.1002/(SICI)1097- 0045(19991201)41:4〈275::AID-PROS8〉3.0.CO;2-T
31. Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2009; 2:1039-49; PMID:19934338; http://dx.doi.org/10.1158/1940- 6207.CAPR-09-0212
32. Li X, Wang L, Gu JW, Li B, Liu WP, Wang YG, et al. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma. Tumour Biol 2010; 31:477-88; PMID:20571968; http://dx.doi.org/10.1007/s13277-010-0060-6
33. Yuan WJ, Ge J, Chen ZK, Wu SB, Shen H, Yang P, et al. Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 2009; 54:2410-7; PMID:19101799; http://dx.doi.org/10.1007/s10620-008-0649-4
34. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21:7011-26; PMID:12370823; http://dx.doi.org/10.1038/sj.onc. 1205679
35. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001; 61:3250-5; PMID:11309274
36. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001; 3:527-30; PMID:11331884; http://dx.doi.org/10.1038/35074604
37. Yang NY, Fernandez C, Richter M, Xiao Z, Valencia F, Tice DA, et al. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal 2011; 23:201-12; PMID:20837138; http://dx.doi.org/10.1016/j.cellsig.2010.09.004
38. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 1999; 10:629-38; PMID:10511313
39. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2002; 160:1009-19; PMID:11891198; http://dx.doi.org/10.1016/S0002-9440(10)64922-X
40. Buettner R, Mesa T, Vultur A, Lee F, Jove R. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008; 6:1766-74; PMID:19010823; http://dx.doi.org/10.1158/1541- 7786.MCR-08-0169
41. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2000; 2:62-9; PMID:10655584; http://dx.doi.org/10.1038/35000008
42. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009; 16:9-20; PMID:19573808; http://dx.doi.org/10.1016/j.ccr.2009.04.009
43. Taddei ML, Parri M, Angelucci A, Onnis B, Bianchini F, Giannoni E, et al. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol 2009; 174:1492-503; PMID:19264906; http://dx.doi.org/10.2353/ajpath.2009.080473
44. Chiari R, Hames G, Stroobant V, Texier C, Maillère B, Boon T, et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 2000; 60:4855-63; PMID:10987298
45. Clifford N, Smith LM, Powell J, Gattenlöhner S, Marx A, O'Connor R. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J Cell Biochem 2008; 105:1250-9; PMID:18814179; http://dx.doi.org/10.1002/jcb.21926
46. Fox BP, Kandpal RP. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 2004; 318:882-92; PMID:15147954; http://dx.doi.org/10.1016/j.bbrc.2004.04.102
47. Nakamoto M, Bergemann AD. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 2002; 59:58-67; PMID: 12242697; http://dx.doi.org/10.1002/jemt.10177
48. Xi HQ, Zhao P. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 2011; 64:498-503; PMID:21415057; http://dx.doi.org/10.1136/jcp.2010.087213
49. Shi G, Yue G, Zhou R. EphA3 functions are regulated by collaborating phosphotyrosine residues. Cell Res 2010; 20:1263-75; PMID:20697431; http://dx.doi.org/10.1038/cr.2010.115
50. Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, et al. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer Res 2005; 65:6745-54; PMID:16061656; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-0758
51. Hu T, Shi G, Larose L, Rivera GM, Mayer BJ, Zhou R. Regulation of process retraction and cell migration by EphA3 is mediated by the adaptor protein Nck1. Biochemistry 2009; 48:6369-78; PMID:19505147; http://dx.doi.org/10.1021/ bi900831k
52. Knöll B, Drescher U. Src family kinases are involved in EphA receptor-mediated retinal axon guidance. J Neurosci 2004; 24:6248-57; PMID:15254079; http://dx.doi.org/10.1523/JNEUROSCI.0985-04.2004
53. Lisabeth EM, Fernandez C, Pasquale EB. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry 2012; 51:1464-75; PMID:22242939; http://dx.doi.org/10.1021/ bi2014079
54. Nojiri K, Iwakawa M, Ichikawa Y, Imadome K, Sakai M, Nakawatari M, et al. The proangiogenic factor ephrin-A1 is up-regulated in radioresistant murine tumor by irradiation. Exp Biol Med (Maywood) 2009; 234:112-22; PMID:18997097; http://dx.doi.org/10.3181/0806-RM-189
55. von Essen CF. Radiation enhancement of metastasis: a review. Clin Exp Metastasis 1991; 9:77-104; PMID: 2032423; http://dx.doi.org/10.1007/BF01756381
56. Zhang T, Hua R, Xiao W, Burdon KP, Bhattacharya SS, Craig JE, et al. Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal dominant congenital cataract. Hum Mutat 2009; 30:E603-11; PMID: 19306328; http://dx.doi.org/10.1002/humu.20995
57. Bae HJ, Song JH, Noh JH, Kim JK, Jung KH, Eun JW, et al. Low frequency mutation of the Ephrin receptor A3 gene in hepatocellular carcinoma. Neoplasma 2009; 56:331-4; PMID:19469653; http://dx.doi.org/10.4149/neo-2009-04-331
58. Kung B, Zhao H, Hicks SL, Tang XX, Ikegaki N. Biological significance of EPHA2 expression in neuroblastoma. Int J Oncol 2009; 35:845-50; PMID: 19724921
59. Dottori M, Down M, Hüttmann A, Fitzpatrick DR, Boyd AW. Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 1999; 94:2477-86; PMID:10498621
60. Essa S, Denzer N, Mahlknecht U, Klein R, Collnot EM, Tilgen W, et al. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J Steroid Biochem Mol Biol 2010; 121: 110-3; PMID:20153427; http://dx.doi.org/10.1016/j.jsbmb.2010.02.003
61. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 2006; 24:3771-9; PMID:16801630; http://dx.doi.org/10.1200/JCO.2005.03.4074
62. Parri M, Buricchi F, Giannoni E, Grimaldi G, Mello T, Raugei G, et al. EphrinA1 activates a Src/focal adhesion kinase-mediated motility response leading to rhodependent actino/myosin contractility. J Biol Chem 2007; 282:19619-28; PMID:17449913; http://dx.doi.org/10.1074/jbc.M701319200
63. Parri M, Taddei ML, Bianchini F, Calorini L, Chiarugi P. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res 2009; 69:2072-81; PMID: 19244130; http://dx.doi.org/10.1158/0008-5472.CAN-08-1845
64. Lawrenson ID, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, et al. Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci 2002; 115:1059-72; PMID:11870224
65. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1:2315-9; PMID:17406473; http://dx.doi.org/10.1038/nprot.2006.339
66. Fox BP, Tabone CJ, Kandpal RP. Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun 2006; 342:1263-72; PMID:16516143; http://dx.doi.org/10.1016/ j.bbrc.2006.02.099
67. Haase C, Bergmann R, Fuechtner F, Hoepping A, Pietzsch J. L-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F-fluoro- Ldopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J Nucl Med 2007; 48:2063-71; PMID:18056335; http://dx.doi.org/10.2967/jnumed. 107.043620